The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 32-40

  Fujimoto, Minoru ^a   Nakano, Mayumi ^b   Terabe, Fumitaka ^b   Kawahata, Hirohisa ^c   Ohkawara, Tomoharu ^b   Han, Yongmei ^b   Ripley, Barry ^d   Serada, Satoshi ^a   Nishikawa, Teppei ^d   Kimura, Akihiro ^d   Nomura, Shintaro ^b   Kishimoto, Tadamitsu ^d   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MATURATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FOXP3+ REGULATORY T CELL; HOMEOSTASIS; IMMUNOREGULATION; IN VIVO STUDY; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SCID MOUSE; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; COLITIS; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-6; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY;

EID: 79251543298     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903314     Document Type: Article

References (25)

1. Kishimoto, T. 2005. Interleukin-6: from basic science to medicine - 40 years in immunology. Annu. Rev. Immunol. 23: 1-21.
2. Ohsugi, Y. 2007. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol. Pharm. Bull. 30: 2001-2006.
3. Park, J. Y., and M. H. Pillinger. 2007. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65(Suppl 1): S4-S10.
4. Nishimoto, N., and T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
5. Bettelli, E., M. Oukka, and V. K. Kuchroo. 2007. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8: 345-350.
6. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, H. Yoshida, T. Nishikawa, F. Terabe, T. Ohkawara, et al. 2008. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105: 9041-9046.
7. Fujimoto, M., S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, Y. Ohsugi, T. Nishikawa, B. Ripley, A. Kimura, et al. 2008. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 58: 3710-3719.
8. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787.
9. Curotto de Lafaille, M. A., and J. J. Lafaille. 2009. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30: 626-635.
10. Williams, L. M., and A. Y. Rudensky. 2007. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8: 277-284.
11. Katsume, A., T. Miyai, H. Suzuki, Y. Moriguchi, H. Kawata, T. Tatsumi, S. Suematsu, T. Kishimoto, and Y. Ohsugi. 1997. Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin. Immunol. Immunopathol. 82: 117-124.
12. Fujimoto, M., T. Naka, R. Nakagawa, Y. Kawazoe, Y. Morita, A. Tateishi, K. Okumura, M. Narazaki, and T. Kishimoto. 2000. Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/ suppressors of cytokine signaling-1 transgenic mice. J. Immunol. 165: 1799-1806.
13. Krutzik, P. O., and G. P. Nolan. 2003. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.
14. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, et al. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929. (Pubitemid 27289596)
15. Yamamoto, M., K. Yoshizaki, T. Kishimoto, and H. Ito. 2000. IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. 164: 4878-4882.
16. Katsume, A., H. Saito, Y. Yamada, K. Yorozu, O. Ueda, K. Akamatsu, N. Nishimoto, T. Kishimoto, K. Yoshizaki, and Y. Ohsugi. 2002. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20: 304-311. (Pubitemid 36299051)
17. Thornton, A. M., P. E. Korty, D. Q. Tran, E. A. Wohlfert, P. E. Murray, Y. Belkaid, and E. M. Shevach. 2010. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. 184: 3433-3441.
18. Josefowicz, S. Z., and A. Rudensky. 2009. Control of regulatory T cell lineage commitment and maintenance. Immunity 30: 616-625.
19. Yang, X.O., R. Nurieva, G. J.Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. Schluns, S. S.Watowich, et al. 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44-56.
20. Komatsu, N., M. E. Mariotti-Ferrandiz, Y. Wang, B. Malissen, H. Waldmann, and S. Hori. 2009. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl. Acad. Sci. USA 106: 1903-1908.
21. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
22. Scott-Browne, J. P., S. Shafiani, G. Tucker-Heard, K. Ishida-Tsubota, J. D. Fontenot, A. Y. Rudensky, M. J. Bevan, and K. B. Urdahl. 2007. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204: 2159-2169.
23. Pasare, C., and R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. (Pubitemid 36222922)
24. Dienz, O., and M. Rincon. 2009. The effects of IL-6 on CD4 T cell responses. Clin. Immunol. 130: 27-33.
25. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.